Project Grant R01CA298329
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $659K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Cancer Institute awarded The Washington University $637,394 on August 5, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop positron emission tomography imaging using a radiotracer (64Cu-DOTA-ECL1I) that quantifies C-C motif chemokine receptor 2 (CCR2) expression in head and neck squamous cell carcinoma patients. The project will establish CCR2-PET as a prognostic biomarker to predict tumor activity, disease recurrence, and response to...
- The National Cancer Institute awarded The Washington University $399,829 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to mechanistically characterize a novel dendritic cell-based immunotherapy for solid tumors. The project will investigate how engineered dendritic cells expressing a B7H3-specific chimeric antigen receptor fused to toll-like receptor 4 signaling domains can overcome tumor immune tolerance by efficiently capturing tumor antigens and cross-priming...
- The National Cancer Institute awarded Washington University $562,550 on July 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop neoantigen-based spherical nucleic acid immunotherapeutics for triple negative breast cancer. The award funds development of a patient-specific nanoparticle immunotherapeutic, termed P-SNA, through an academic-industrial partnership between FlashPoint Therapeutics and the Gillanders Laboratory at Washington University School of Medicine. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $712,569 on May 4, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the impact of KEAP1/NRF2 pathway activation on chemotherapy response in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The research tests whether NRF2 activation or deletion governs cisplatin-etoposide (CIS-ETO) response in patient-derived xenograft (PDX) models of SCLC and LCNEC, with the primary...
- The National Cancer Institute awarded The Washington University $623,616 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support development of PET imaging methods for detecting and quantifying CD163+ tumor-associated macrophages in head and neck cancer. The research addresses the role of tumor-associated macrophages (TAMs) in the tumor microenvironment, which coordinate angiogenesis, extracellular matrix remodeling, cancer cell proliferation,...
- The National Cancer Institute awarded The Washington University $542,644 for Project Grant R01CA298938 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395), a Project Grant assistance type. The award funds development and preclinical testing of radiation-guided antibody-drug conjugates (ADCs) targeting TAX-interacting protein 1 (TIP1) as a strategy to enhance non-small cell lung cancer (NSCLC) treatment. The research leverages a discovery that TIP1 is significantly...
- The National Cancer Institute awarded The Washington University $498,290 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate epigenetic regulation of premalignant states in cutaneous squamous cell carcinoma. The funded research defines the causes and consequences of KDM6A mislocalization in skin cancer through two primary aims. Aim 1 involves exome sequencing of banked human tumors to identify genomic correlates of KDM6A mislocalization, in...
- The National Cancer Institute awarded The University of Chicago $518,151 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate nicotinamide N-methyltransferase (NNMT) inhibition as a strategy to sensitize ovarian and colorectal cancers to immune checkpoint inhibitors. The award funds research targeting NNMT expression in cancer-associated fibroblasts within the tumor microenvironment. The project will investigate whether NNMTI'960, a small-molecule NNMT...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...